Publication: Pharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves
dc.contributor.author | Corum O., Yildiz R., Ider M., Altan F., Ok M., Uney K. | |
dc.contributor.author | Corum, O, Yildiz, R, Ider, M, Altan, F, Ok, M, Uney, K | |
dc.date.accessioned | 2023-05-09T18:33:59Z | |
dc.date.available | 2023-05-09T18:33:59Z | |
dc.date.issued | 2019-11-01 | |
dc.date.issued | 2019.01.01 | |
dc.description.abstract | The aim of this study was to evaluate the pharmacokinetics and bioavailability of cefquinome (CFQ) and ceftriaxone (CTX) following intravenous (IV) and intramuscular (IM) administrations in premature calves. Using a parallel design, 24 premature calves were randomly divided into the two antibiotic groups. Each of the six animals in the first group received CFQ (2 mg/kg) through IV or IM administration. The second group received CTX (20 mg/kg) via the same administration route. Plasma concentrations of the drugs were analyzed by high-performance liquid chromatography and noncompartmental methods. Mean pharmacokinetic parameters of CFQ and CTX following IV administration were as follows: elimination half-life (t1/2λz) 1.85 and 3.31 hr, area under the plasma concentration–time curve (AUC0–∞) 15.74 and 174 hr * μg/ml, volume of distribution at steady-state 0.37 and 0.45 L/kg, and total body clearance 0.13 and 0.12 L hr−1 kg−1, respectively. Mean pharmacokinetic parameters of CFQ and CTX after IM injection were as follows: peak concentration 4.56 and 25.04 μg/ml, time to reach peak concentration 1 and 1.5 hr, t1/2λz 4.74 and 3.62 hr, and AUC0–∞ 22.75 and 147 hr * μg/ml, respectively. The bioavailability of CFQ and CTX after IM injection was 141% and 79%, respectively. IM administration of CFQ (2 mg/kg) and CTX (20 mg/kg) can be recommended at 12-hr interval for treating infections caused by susceptible bacteria, with minimum inhibitory concentration values of ≤0.5 and ≤4 μg/ml, respectively, in premature calves. However, further research is indicated to assess the pharmacokinetic parameters following multiple doses of the drug in premature calves. | |
dc.identifier.doi | 10.1111/jvp.12789 | |
dc.identifier.eissn | 1365-2885 | |
dc.identifier.endpage | 639 | |
dc.identifier.issn | 0140-7783 | |
dc.identifier.scopus | 2-s2.0-85067614931 | |
dc.identifier.startpage | 632 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12597/13429 | |
dc.identifier.volume | 42 | |
dc.identifier.wos | WOS:000501034000008 | |
dc.relation.ispartof | Journal of Veterinary Pharmacology and Therapeutics | |
dc.relation.ispartof | JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS | |
dc.rights | false | |
dc.subject | bioavailability | cefquinome | ceftriaxone | pharmacokinetics | premature calves | |
dc.title | Pharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves | |
dc.title | Pharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves | |
dc.type | Article | |
dspace.entity.type | Publication | |
oaire.citation.issue | 6 | |
oaire.citation.volume | 42 | |
relation.isScopusOfPublication | 792c8c5d-0721-4194-a679-ff6a70b68810 | |
relation.isScopusOfPublication.latestForDiscovery | 792c8c5d-0721-4194-a679-ff6a70b68810 | |
relation.isWosOfPublication | 128ec7da-87c8-4996-9ff1-72790a915be6 | |
relation.isWosOfPublication.latestForDiscovery | 128ec7da-87c8-4996-9ff1-72790a915be6 |